Can I read Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer on EtoBox?

Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer by Harold J. Burstein; Jennifer R. Bellon; Sharon Galper; Hsiao-Ming Lu; Irene Kuter; Alphonse G. Taghian; Julia Wong; Rebecca Gelman; Craig A. Bunnell; Leroy M. Parker; Judy E. Garber; Eric P. Winer; Jay R. Harris; Simon N. Powell is a Medicine article available to read on EtoBox.

What is Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer about?

## Purpose: To evaluate the safety and feasibility of concurrent radiation therapy and paclitaxel-based adjuvant chemotherapy, given either weekly or every 3 weeks, after adjuvant doxorubicin and cyclophosphamide (ac). ## Methods and materials: After definitive breast surgery and ac chemotherapy, 40 patients with operable stage ii or iii breast cancer received protocol-based treatment with concurrent paclitaxel and radiation therapy. paclitaxel was evaluated on 2 schedules, with treatment given either weeklyx12 weeks (60 mg/m2), or every 3 weeksx4 cycles (135-175 mg/m2). radiation fields and schedules were determined by the patient's surgery and pathology. the tolerability of concurrent therapy was evaluated in cohorts of 8 patients as a phase i study. ## Results: Weekly paclitaxel treatment at 60 mg/m2 per week with concurrent radiation led to dose-limiting toxicity in 4 of 16 patients (25%), including 3 who developed pneumonitis (either grade 2 [1 patient] or grade 3 [2 patients]) requiring steroids. efforts to eliminate this toxicity in combination with weekly paclitaxel through treatment scheduling and ct-based radiotherapy simulation were not successful. by contrast, dose-limi

Who reads Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer?

Author

Harold J. Burstein; Jennifer R. Bellon; Sharon Galper; Hsiao-Ming Lu; Irene Kuter; Alphonse G. Taghian; Julia Wong; Rebecca Gelman; Craig A. Bunnell; Leroy M. Parker; Judy E. Garber; Eric P. Winer; Jay R. Harris; Simon N. Powell

Publisher

Elsevier Science; Elsevier ; Elsevier BV (ISSN 0360-3016)

Published

2006

Language

EN

Field

Medicine (Health Sciences)